These results suggest that patients in the EM‐E and EM‐B groups might exhibit a relatively high grade of CRS and ICANS following anti‐BCMA CAR‐T therapy, which should be considered when determining their therapeutic course. The gene discussed is TNFRSF17; the disease is congenital rubella syndrome.